HilleVax (NASDAQ:HLVX – Get Rating) is one of 279 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare HilleVax to related companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, earnings and dividends. Analyst Ratings This is a summary […]
Item 8.01 Other Events.
On April 25, 2023, HilleVax, Inc. announced that it completed
enrollment of its NEST-IN1 clinical trial , with over 3,000. | April 25, 2023
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HilleVax (NASDAQ:HLVX – Get Rating) is one of 282 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare HilleVax to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk. Valuation & Earnings This […]